CA2409813C - Compositions and methods for treatment of mucosal infections - Google Patents

Compositions and methods for treatment of mucosal infections Download PDF

Info

Publication number
CA2409813C
CA2409813C CA2409813A CA2409813A CA2409813C CA 2409813 C CA2409813 C CA 2409813C CA 2409813 A CA2409813 A CA 2409813A CA 2409813 A CA2409813 A CA 2409813A CA 2409813 C CA2409813 C CA 2409813C
Authority
CA
Canada
Prior art keywords
nthi
killed
administration
pbs
mucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2409813A
Other languages
English (en)
French (fr)
Other versions
CA2409813A1 (en
Inventor
Robert Llewellyn Clancy
Gerald Pang
Margaret Lorraine Dunkley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PNEUMOBIOTICS Pty Ltd
Original Assignee
PNEUMOBIOTICS Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PNEUMOBIOTICS Pty Ltd filed Critical PNEUMOBIOTICS Pty Ltd
Publication of CA2409813A1 publication Critical patent/CA2409813A1/en
Application granted granted Critical
Publication of CA2409813C publication Critical patent/CA2409813C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2409813A 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections Expired - Lifetime CA2409813C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ7612 2000-05-19
AUPQ7612A AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections
PCT/AU2001/000588 WO2001087332A1 (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections

Publications (2)

Publication Number Publication Date
CA2409813A1 CA2409813A1 (en) 2001-11-22
CA2409813C true CA2409813C (en) 2013-11-12

Family

ID=3821690

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2409813A Expired - Lifetime CA2409813C (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections

Country Status (10)

Country Link
US (1) US8637051B2 (https=)
EP (1) EP1305042B1 (https=)
JP (2) JP5567756B2 (https=)
KR (1) KR20030019389A (https=)
CN (1) CN1437480A (https=)
AT (1) ATE535284T1 (https=)
AU (1) AUPQ761200A0 (https=)
BR (1) BR0110971A (https=)
CA (1) CA2409813C (https=)
WO (1) WO2001087332A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
WO2005077409A1 (en) * 2004-02-18 2005-08-25 The University Of Newcastle Research Associates Limited A vaccine formulated for administration to mucosa of the lungs
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
CA2577165C (en) * 2004-08-17 2015-01-27 Hunter Immunology Pty Limited Oral killed vaccines and method for providing same
US20070269376A1 (en) * 2004-08-17 2007-11-22 Hunter Immunology Limited Method for Determining Dosage for an Oral Killed Vaccine
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
WO2011115762A1 (en) 2010-03-18 2011-09-22 Eveready Battery Company, Inc. Button cell battery dispenser package
EP2585094B1 (en) * 2010-06-25 2018-08-01 INSERM - Institut National de la Santé et de la Recherche Médicale Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections
WO2013028756A1 (en) 2011-08-22 2013-02-28 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
JP6632607B2 (ja) * 2014-05-02 2020-01-22 クー バイオロジックス インク．Ｑｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 抗微生物免疫修飾
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
WO2024234034A1 (en) * 2023-05-12 2024-11-21 Biomune Pty Ltd Compositions and methods for preventative treatments for mucosal associated ailments

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
JPH0680575A (ja) * 1991-03-05 1994-03-22 Meiji Milk Prod Co Ltd 経口免疫賦活剤
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
US6287568B1 (en) 1997-09-09 2001-09-11 The Trustees Of Columbia University In The City Of New York Methods relating to immunogenic dextran-protein conjugates
US6153182A (en) * 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
EP1044273A2 (en) 1997-12-23 2000-10-18 Genesis Research & Development Corporation Limited COMPOSITIONS DERIVED FROM $i(MYCOBACTERIUM VACCAE) AND METHODS FOR THEIR USE
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
PT1053325E (pt) * 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
SE9800615D0 (sv) * 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
JP2002505302A (ja) * 1998-03-05 2002-02-19 ザ メディカル カレッジ オブ オハイオ Ｉｌ−１２の鼻腔内イノキュレーションによる免疫の増強
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
WO2000000218A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
AR020102A1 (es) * 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
DE60142786D1 (de) * 2000-06-19 2010-09-23 Hunter Immunology Ltd Zusammensetzungen und methoden zur behandlung von candidosen
EP1311684A4 (en) * 2000-08-08 2005-10-19 Genesis Res & Dev Corp Ltd LACTOBACILLUS RHAMNOSUS POLYNUCLEOTIDES, POLYPEPTIDES, AND METHODS FOR THEIR USE

Also Published As

Publication number Publication date
JP5567756B2 (ja) 2014-08-06
EP1305042B1 (en) 2011-11-30
ATE535284T1 (de) 2011-12-15
US20040057965A1 (en) 2004-03-25
WO2001087332A1 (en) 2001-11-22
JP2012153706A (ja) 2012-08-16
EP1305042A4 (en) 2005-02-02
KR20030019389A (ko) 2003-03-06
CA2409813A1 (en) 2001-11-22
EP1305042A1 (en) 2003-05-02
AUPQ761200A0 (en) 2000-06-15
US8637051B2 (en) 2014-01-28
CN1437480A (zh) 2003-08-20
BR0110971A (pt) 2005-04-05
JP2003533489A (ja) 2003-11-11

Similar Documents

Publication Publication Date Title
CA2409813C (en) Compositions and methods for treatment of mucosal infections
Correa et al. Vaccines, adjuvants and key factors for mucosal immune response
US20030180260A1 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
Mach Clinical usefulness of probiotics
Anggraeni et al. Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants
WO1993020843A1 (en) Oral treatment of helicobacter infection
JP3919812B2 (ja) Ｈ．ピロリ関連胃十二指腸疾患の治療
EP3651796A1 (en) Live attenuated cholera vaccine with probiotic properties
WO2009004002A1 (en) Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli
AU2001258060B2 (en) Compositions and methods for treatment of mucosal infections
EP0686039B1 (en) Method of enhancing immune response to oral vaccines
AU2001258060A1 (en) Compositions and methods for treatment of mucosal infections
US6406703B1 (en) Treatment of H. pylori associated gastroduodenal disease
Jahantigh et al. The effect of the microbiome on vaccine efficacy
Talebi Bezmin Abadi et al. Future of Helicobacter pylori and its feasibility
Das et al. A prophylactic study of curcumin nanoparticle-induced bacterial ghosts against Helicobacter pylori in a C57BL/6 mouse model
AU2001265695A1 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
Singh et al. Salmonella Typhi: Virulence, Multi drug Resistance and Vaccines
AU675938C (en) Oral treatment of helicobacter infection
Kroeker et al. Treatment of Ulcerative Colitis
Woo et al. Enhancement of humoral and protective immune response induced by live‐attenuated Salmonella typhi by ampicillin
Germani et al. Live-Attenuated Shigella Vaccines. Is Encouraging Good Enough?
Holder et al. Oral Pseudomonas aeruginosa immunization enhances survival in mice subsequently burned and infected with P. aeruginosa
Walker Immunomodulation of the Intestinal Mucosa: A Challenge and An Opportunity
WALKER POTENTIAL BENEFIT FROM INACTIVATED WHOLE CELL VACCINES

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210521